Member Info for AquaeSulis01

Well let's hope we wake up to that confirmatory RNS that at least the main fundraise for £2.5m less expenses has been fully subscribed by new and existing ii 's at 16p so that the company remains a going concern, who knows even cross might subscribe if they are that confidence in the technology. I am less confident that anything significant will be raised by the REX retail offer at the same price

Toyin Grant you that I looked past the need for yet another fundraise should discussions conclude a lot speedier than other company engagements but it really doesn't fill me with hope alongside all the other missed deadlines

Well with the skin rns's out today that is one safety net gone

TW has not commented on this yet, he is in Greece and will no doubt be considering his view overnight before he travels back, but I suspect he will not be a happy bunny. I am sorry to say I see no positives in either the end of year RNS or placing which certainly wont get away anyway near the 16p. My reading is that SA has taken a view that the Croda scale-up and launch would proceed as planned with sufficient revenues arriving early 2023 to prevent the need for a placing just to keep the lights on and he has lost that gamble following this month's technical meeting. So instead of taking risk mitigation action by raising a placing at a discount in advance of the technical news when the sp was in the 20s, he is now faced with the nightmare scenario of trying to get a placing away at any price to keep the lights on and as a shareholder I am extremely unhappy. As the influencer campaign has now ceased I would suggest immediate cost cutting measures should include the termination of a certain director's contract brought in for her "influencer knowledge and expertise". Regarding the potential acquisition, I think we can all guess the current value of that company if it is change out of the hoped for £2.5M fund raise. Skinbiotix is now starting to sound like sweetbiotix, it may be with us one day, but one question I do have is as successful scale-up to 600 litres was achieved by Sederma , why can't the commercial release to VIP clients proceed early 2023, this needs answering? Finally, we were told over a year ago that discussions were underway for some of the other pillars i.e.last years eoy results; Medibiotix - Management is "in discussion with a number of global woundcare companies", this years latest update "Early discussions with potential global partners in the meditech sector have commenced", so no progress at allon the face of it.

Legal which of your junior mining interests is giving you more confidence; Cora Gold, Helium One, Caracal Gold, Oriole, Kavango Resources or ECR all of which seem to be plodding along with the odd fund raise or two to keep them going? PJ has assembled a portfolio of projects each with their own dedicated project manager assigned to provide the focus needed. The strategy has minimised the need for POW to repeatedly go back to investors to raise funds whilst we have two exciting direct active explorations ongoing, Molopo and Tati with assay results awaited, and a number of indirect interests via holdings in such as Kavango Resources.

To be fair the small fundraise has de-risked things short term, and throw in the fact that whilst prebiotic orders will be down on last year they will be significantly higher H2 than H1 with the bigger partner orders and the milestone payment from the US Partner for sweetbiotix. Hopefully, news from the skinbiotix croda deal will boost the value of the skinbiotherapeutics holding and then the big one is launch in 2023 of the sweetbiotix products by the US Partner which will transform the finances so lots of upside to go with the current gloom.

skid, you have the wrong company Board, Cholbiome now the responsibility of Probiotix Health and the Commercial Director, Mikkel Hived Hansen, is probably the guy to contact.
https://probiotixhealth-ir.com/corporate/the-board
To be honest, I am surprised that they are bothering to re-stock CholbiomeX3 as it contains levels of of Monacolin K banned in the rest of Europe (same molecular stricture as lovastatin), so maybe they are re-formulating it?

General Market rally down to US CPI data lower than expected

https://www.standard.co.uk/business/ftse-100-live-13-december-unemployment-rate-real-terms-pay-cost-of-living-squeeze-us-inflation-figures-b1046754.html

elrico, I chose to ignore the inferred batch no's * batch number size for the simple reason tracking actual order numbers has proved the most reliable guide to revenue but will be delighted to be proved wrong

elrico, did any of your batch numbers have a BBF date different to 08/23?

Build up sales

As the initial order would probably satisfy 20000 two box orders then race must be on to builders up before shelf life expires would be one ticking clock I guess Toyin

Unfortunately, it is the missed targets that people are focusing on Toyin
" Potential additional cosmetic claims for SkinBiotix® being investigated. Initial royalty revenues anticipated as planned in calendar year 2022

Post year end:

· Successful product launch of AxisBiotix-Ps™ 12 months earlier than intended. Early sales in the UK and US have commenced; expansion into Europe to occur in H1 2022

· Targeting acne as the next AxisBiotix opportunity; plans to develop a bacterial blend and initiate a consumer study during 2022""

The new wellbiome has only recently been launched so will be interesting to see how it is received with its associated heart health benefits. Also, noting the ingredients for the protein enhanced iced mocha at your link one, it contains 40% sugar; just imagine the impact of replacing this detrimental to health ingredient with sweetbiotix, which brings its own fibrous health benefits

Plenty to look forward to reading over Christmas then Clio

Must be honest I'm looking forward to finding out what Stuart's load running our little company entails as there has been no news since August

Everyone is entitled to their opinion, however, happy holder here especially with this latest update which just a reminder the technical information has been approved by a qualified geologist so is not some figment of PJ's imagination

""QUALIFIED PERSON STATEMENT

The technical information contained in this disclosure has been read and approved by Mr Nick O'Reilly (MSc, DIC, MIMMM, MAusIMM, FGS), who is a qualified geologist and acts as the Qualified Person under the AIM Rules - Note for Mining and Oil & Gas Companies. Mr O'Reilly is a Principal consultant working for Mining Analyst Consulting Ltd which has been retained by Power Metal Resources PLC to provide technical support."

elrico, keep your hair on, your response to mol is a little disappointing and uncalled for. Firstly, the nature of mol's posts are invariably novel with good or bad findings and comments in equal measure irrespective of the company he is commenting on (he is not pro Opti against SBTX). Consequently, you wouldn't expect him to comment on SOH's fund raise or nil response to Q&A's as others had already posted their thoughts and mol had nothing new to add but he did flag up what he had found regarding the PBX CEO in waiting which is hardly positive.
mol does make a very valid point about the RNS which at this late stage still doesn't give an exact date for the Results to be released which infers they will be rushed and may well end up appearing after markets close on the 23rd which doesn't inspire confidence. In the defence of the CFO he is new to the company and there was no hand over period from Doug which is unusual, however, Doug always managed to get the accounts out in a timely fashion despite being P/T.
With regards knowing what is in the Results, what is out there is the £1.8M cash at end Jun 2022 following a £1.4M cash burn since Dec 2021, and £75K revenue from axis sells at end Jun 2022 which will have risen to circa £190k present date based on the "UK" area code order tracking guestimates,. What we don't know is the split between Operating expenses and R&D, what the new Operating Expenses are post Jun 2022 following the appointment of extra directors and staff and continuing R&D commitments, and consequently whether there is an ongoing concern statement for the next 12 mths that the NOMAD has happily signed off in the absence of any fundraise which we have been told isn't necessarily required

elric, meant to ask, will we see you with a full head of hair on your next podcast? :}

Sorry elric, had meant that warranted a RNS although had heard about the two Croda meetings on a TW Bearcast on 2nd Dec but as you quite rightly pointed out that was not generally known